Immunocompatible Tissue Scaffold for Heart Valve Durability
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current heart valve replacement options, such as bioprosthetic and mechanical valves, face durability issues and immune rejection, with bioprosthetics degrading due to xenogenic immune reactions and mechanical valves requiring lifelong anticoagulation, leading to complications and high healthcare costs.
Innovation Solution
A method of forming an immunocompatible scaffold by decellularizing xenogenic tissue and recellularizing it with eukaryotic cells compatible to the recipient, using alpha-galactosidase treatment and glutaraldehyde fixation to create a shelf-stable, durable heart valve replacement that reduces inflammatory immune responses.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Object-affected harmful factors
If bioprosthetic valves are used, then characteristics similar to native heart valve and lower bleeding rates are achieved, but durability is reduced due to xenogenic immune reaction
Solution Approach 1:
The patent removes xenogenic cells from the tissue matrix through decellularization processes, extracting the harmful immunogenic components while preserving the structural framework. This eliminates the source of inflammatory immune responses while maintaining the valve's mechanical function and durability.
Solution Approach 2:
The patent modifies the immunogenic parameters of the tissue by treating it with decellularization agents and enzymes to remove surface markers and antigens. This parameter change transforms the tissue from immunogenic to immunocompatible, resolving the contradiction between immune compatibility and durability.
2Duration of action of stationary object
If mechanical valves are used, then durability is improved, but thrombogenicity increases requiring lifelong anticoagulation
Solution Approach 1:
The patent changes the surface properties and cellular composition of the valve through decellularization and recellularization with autologous or immunocompatible cells. This parameter modification reduces thrombogenicity while maintaining the mechanical durability of the valve structure.
3Adaptability or versatility
If xenogenic tissue is used, then availability is improved, but immune rejection occurs leading to structural valvular deterioration
Solution Approach 1:
The patent extracts xenogenic cells and surface markers from readily available animal tissue through systematic decellularization. This removes the source of immune rejection while preserving the abundant supply of xenogenic tissue, resolving the contradiction between availability and immune compatibility.
Solution Approach 2:
The patent uses decellularization agents, enzymes, and recellularization with compatible cells as intermediaries to transform xenogenic tissue into an immunocompatible state. This intermediary process enables the use of abundant xenogenic tissue sources without triggering immune rejection.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The immunocompatible scaffold significantly reduces inflammatory immune responses, increases durability, and eliminates the need for anticoagulation, offering a cost-effective, long-lasting solution for heart valve replacements with reduced reoperation and complication rates.
Implementation Method 1
contacting the decellularized tissue matrix with alpha-galactosidase
Implementation Method 2
the xenogenic scaffold may be fixed with a fixing agent, such as glutaraldehyde
Data Source
AI summary
A method of forming an immunocompatible scaffold for a recipient. A decellularized tissue matrix is contacted in vitro with eukaryotic cells immunocompatible to the recipient to cover an exterior surface of the decellularized tissue matrix to form the immunocompatible scaffold. The decellularized tissue is formed from tissue xenogenic to the recipient. The decellularized tissue matrix may be contacted with alpha-galactosidase prior to recellularizing the decellularized tissue matrix. This process may be completed in a manner of days, rather than weeks. The immunocompatible scaffold may be fixed with a fixing agent such as glutaraldehyde, forming a shelf stable product.